Section editor George P. Canellos has disclosed no financial relationships relevant to the content of this article.The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.
Target audience:Physicians who wish to advance their current knowledge of clinical cancer medicine in lymphoma oncology.
LEARNING OBJECTIVESAfter completing this course, the reader should be able to:1. In your patients with gastric MALT lymphoma (GML), determine accurate staging and formulate appropriate treatment strategies.2. Assess early stage GML patients who should be closely monitored for early intervention and manage treatment plans.3. Design further studies with different modality treatments to explore the impact of occult blood disease on patients' outcomes.This article is available for continuing medical education credit at CME.TheOncologist.com.
CME CME
ABSTRACTEarly-stage gastric mucosa-associated lymphoid tissue lymphoma (GML) is considered a localized disease with an indolent course. Circulating malignant cells have been detected in other early-stage indolent lymphomas by molecular methods. We investigated the incidence of occult blood disease in early-stage GML patients, its impact on clinical outcome, and the similarity between blood and gastric lymphocytic clones. Sixty-two patients with local-